Jama Oncology最新文献

{"title":"Transplant-Free Salvage Therapy for Low-Risk Relapsed Pediatric Hodgkin Lymphoma: A Nonrandomized Clinical Trial.","authors":"Bradford S Hoppe, Sarah A Milgrom, Lindsay A Renfro, Yue Wu, Cindy L Schwartz, Louis S Constine, Kathleen M McCarten, Kara M Kelly, David Hodgson, Sharon M Castellino, Frank G Keller","doi":"10.1001/jamaoncol.2024.5648","DOIUrl":"10.1001/jamaoncol.2024.5648","url":null,"abstract":"","PeriodicalId":48661,"journal":{"name":"Jama Oncology","volume":" ","pages":"340-342"},"PeriodicalIF":28.4,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11837869/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142916004","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Uncertain Prognostic Impact of Visceral Pleural Invasion-Reply.","authors":"Nasser Altorki, Xiaofei Wang, Thomas E Stinchcombe","doi":"10.1001/jamaoncol.2024.6173","DOIUrl":"10.1001/jamaoncol.2024.6173","url":null,"abstract":"","PeriodicalId":48661,"journal":{"name":"Jama Oncology","volume":" ","pages":"351-352"},"PeriodicalIF":28.4,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142957251","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Errors in Text.","authors":"","doi":"10.1001/jamaoncol.2025.0157","DOIUrl":"10.1001/jamaoncol.2025.0157","url":null,"abstract":"","PeriodicalId":48661,"journal":{"name":"Jama Oncology","volume":"11 3","pages":"354"},"PeriodicalIF":28.4,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11926622/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143665208","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Concerns in Interpretation of Results In the Identification of Immune Checkpoint Inhibitor-Induced Diabetes-Reply.","authors":"Karina N Ruiz-Esteves, Aaron J Deutsch, Michelle Rengarajan","doi":"10.1001/jamaoncol.2024.6476","DOIUrl":"10.1001/jamaoncol.2024.6476","url":null,"abstract":"","PeriodicalId":48661,"journal":{"name":"Jama Oncology","volume":" ","pages":"353-354"},"PeriodicalIF":28.4,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143068939","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Nontransplant Treatment for Relapsed Pediatric Hodgkin Lymphoma-Less Is More.","authors":"Ilia N Buhtoiarov, Rabi Hanna","doi":"10.1001/jamaoncol.2024.5624","DOIUrl":"10.1001/jamaoncol.2024.5624","url":null,"abstract":"","PeriodicalId":48661,"journal":{"name":"Jama Oncology","volume":" ","pages":"240-241"},"PeriodicalIF":28.4,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142916035","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"JAMA Oncology.","authors":"","doi":"10.1001/jamaoncol.2024.4633","DOIUrl":"https://doi.org/10.1001/jamaoncol.2024.4633","url":null,"abstract":"","PeriodicalId":48661,"journal":{"name":"Jama Oncology","volume":"11 3","pages":"213"},"PeriodicalIF":28.4,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143665210","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Errors in Results and Figure 2.","authors":"","doi":"10.1001/jamaoncol.2025.0295","DOIUrl":"10.1001/jamaoncol.2025.0295","url":null,"abstract":"","PeriodicalId":48661,"journal":{"name":"Jama Oncology","volume":"11 3","pages":"354"},"PeriodicalIF":28.4,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11926623/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143665203","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Adjuvant Chemotherapy After Resection of Localized Pancreatic Adenocarcinoma Following Preoperative FOLFIRINOX.","authors":"Thomas F Stoop, Toshitaka Sugawara, Atsushi Oba, Isabel M Feld, Stijn van Roessel, Eran van Veldhuisen, Y H Andrew Wu, Jo Nishino, Mahsoem Ali, Adnan Alseidi, Alain Sauvanet, Antonello Mirabella, Antonio Sa Cunha, Arto Kokkola, Bas Groot Koerkamp, Daniel Pietrasz, Dyre Kleive, Giovanni Butturini, Giuseppe Malleo, Hanneke W M van Laarhoven, Isabella Frigerio, Jeanne Dembinski, Jin He, Johan Gagnière, Jörg Kleeff, Jose M Ramia, Keith J Roberts, Knut J Labori, Marco V Marino, Massimo Falconi, Michael B Mortensen, Mickaël Lesurtel, Morgan Bonds, Nikolaos Chatzizacharias, Oliver Strobel, Olivier Turrini, Oonagh Griffin, Oskar Franklin, Per Pfeiffer, Richard D Schulick, Roberto Salvia, Roeland F de Wilde, Safi Dokmak, Salvador Rodriguez Franco, Simone Augustinus, Stefan K Burgdorf, Stefano Crippa, Thilo Hackert, Timo Tarvainen, William R Burns, Wells Messersmith, Johanna W Wilmink, Richard A Burkhart, Marco Del Chiaro, Marc G Besselink","doi":"10.1001/jamaoncol.2024.5917","DOIUrl":"10.1001/jamaoncol.2024.5917","url":null,"abstract":"<p><strong>Importance: </strong>The effect of adjuvant chemotherapy following resection of pancreatic adenocarcinoma after preoperative (m)FOLFIRINOX (combination leucovorin calcium [folinic acid], fluorouracil, irinotecan hydrochloride, and oxaliplatin in full or modified dosing) chemotherapy on overall survival (OS) is unclear because current studies do not account for the number of cycles of preoperative chemotherapy and adjuvant chemotherapy regimen.</p><p><strong>Objective: </strong>To investigate the association of adjuvant chemotherapy following resection of pancreatic adenocarcinoma after preoperative (m)FOLFIRINOX with OS, taking into account the number of cycles of preoperative chemotherapy and adjuvant chemotherapy regimen.</p><p><strong>Design, setting, and participants: </strong>This retrospective cohort study included patients with localized pancreatic adenocarcinoma treated with 2 to 11 cycles of preoperative (m)FOLFIRINOX followed by resection across 48 centers in 20 countries from 2010 to 2018. Patients who died within 3 months after surgery were excluded (landmark). Data were analyzed from February 1 to December 31, 2023.</p><p><strong>Exposures: </strong>Preoperative (m)FOLFIRINOX chemotherapy followed by resection and eventually followed by adjuvant chemotherapy.</p><p><strong>Main outcomes and measures: </strong>The primary outcome was OS, calculated from the 3-month landmark. Cox regression analysis, including interaction analyses, was performed to investigate the association of adjuvant chemotherapy with OS.</p><p><strong>Results: </strong>Overall, 767 patients were included after resection of pancreatic adenocarcinoma (median [IQR] age, 62 [55-67] years; 404 [52.7%] male). Adjuvant chemotherapy was independently associated with prolonged OS (hazard ratio [HR], 0.66; 95% CI, 0.49-0.87), confirmed by adjusted OS curves. The interaction analysis to assess estimated treatment effect across subgroups was not statistically significant. The forest plot and interaction test suggest that the association of adjuvant chemotherapy was lower among patients receiving 8 or more cycles of preoperative (m)FOLFIRINOX, those who had radiological response, and those with ypN0 disease. Compared to no adjuvant chemotherapy, both adjuvant (m)FOLFIRINOX (HR, 0.57; 95% CI, 0.40-0.80) and other multiagent adjuvant regimens (HR, 0.61; 95% CI, 0.41-0.92) were associated with prolonged OS, whereas single-agent adjuvant chemotherapy was not (HR, 0.75; 95% CI, 0.55-1.03).</p><p><strong>Conclusions and relevance: </strong>In this cohort study, adjuvant (m)FOLFIRINOX and other multiagent chemotherapy regimens were associated with improved OS following resection of localized pancreatic adenocarcinoma after preoperative (m)FOLFIRINOX, whereas single-agent adjuvant chemotherapy was not. The impact of adjuvant chemotherapy on OS may be lower in subgroups such as patients with 8 or more preoperative cycles of (m)FOLFIRINOX, those having radiological response, ","PeriodicalId":48661,"journal":{"name":"Jama Oncology","volume":" ","pages":"276-287"},"PeriodicalIF":28.4,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11926629/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143025389","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Transplant and Nontransplant Salvage Therapy in Pediatric Relapsed or Refractory Hodgkin Lymphoma: The EuroNet-PHL-R1 Phase 3 Nonrandomized Clinical Trial.","authors":"Stephen Daw, Alexander Claviez, Lars Kurch, Dietrich Stoevesandt, Andishe Attarbaschi, Walentyna Balwierz, Auke Beishuizen, Michaela Cepelova, Francesco Ceppi, Ana Fernandez-Teijeiro, Alexander Fosså, Thomas W Georgi, Lisa Lyngsie Hjalgrim, Andrea Hraskova, Thierry Leblanc, Maurizio Mascarin, Jane Pears, Judith Landman-Parker, Tomaž Prelog, Wolfram Klapper, Alan Ramsay, Regine Kluge, Karin Dieckmann, Tanja Pelz, Dirk Vordermark, Dieter Körholz, Dirk Hasenclever, Christine Mauz-Körholz","doi":"10.1001/jamaoncol.2024.5636","DOIUrl":"10.1001/jamaoncol.2024.5636","url":null,"abstract":"<p><strong>Importance: </strong>The current standard-of-care salvage therapy in relapsed/refractory classic Hodgkin lymphoma (cHL) includes consolidation high-dose chemotherapy (HDCT)/autologous stem cell transplant (aSCT).</p><p><strong>Objective: </strong>To investigate whether presalvage risk factors and fludeoxyglucose-18 (FDG) positron emission tomography (PET) response to reinduction chemotherapy can guide escalation or de-escalation between HDCT/aSCT or transplant-free consolidation with radiotherapy to minimize toxic effects while maintaining high cure rates.</p><p><strong>Design, setting, and participants: </strong>EuroNet-PHL-R1 was a nonrandomized clinical trial that enrolled patients younger than 18 years with first relapsed/refractory cHL across 68 sites in 13 countries in Europe between January 2007 and January 2013. Data were analyzed between September 2022 and July 2024.</p><p><strong>Intervention: </strong>Reinduction chemotherapy consisted of alternating IEP (ifosfamide, etoposide, prednisolone) and ABVD (adriamycin, bleomycin, vinblastine, dacarbazine). Patients with low-risk disease (late relapse after 2 cycles of first-line chemotherapy and any relapse with an adequate response after 1 IEP/ABVD defined as complete metabolic response on FDG-PET and at least 50% volume reduction) received a second IEP/ABVD cycle and radiotherapy (RT) to all sites involved at relapse. Patients with high-risk disease (all primary progressions and relapses with inadequate response after 1 IEP/ABVD cycle) received a second IEP/ABVD cycle plus HDCT/aSCT with or without RT.</p><p><strong>Main outcomes and measures: </strong>The primary end point was 5-year event-free survival. Secondary end points were overall survival (OS) and progression-free survival (PFS). PFS was identical to event-free survival because no secondary cancers were observed. PFS data alone are presented for simplicity.</p><p><strong>Results: </strong>Of 118 patients analyzed, 58 (49.2%) were female, and the median (IQR) age was 16.3 (14.5-17.6) years. The median (IQR) follow-up was 67.5 (58.5-77.0) months. The overall 5-year PFS was 71.3% (95% CI, 63.5%-80.1%), and OS was 82.7% (95% CI, 75.8%-90.1%). For patients in the low-risk group (n = 59), 41 received nontransplant salvage with a 5-year PFS of 89.7% (95% CI, 80.7%-99.8%) and OS of 97.4% (95% CI, 92.6%-100%). In contrast, 18 received HDCT/aSCT off protocol, with a 5-year PFS of 88.9% (95% CI, 75.5%-100%) and OS of 100%. All 59 patients with high-risk disease received HDCT/aSCT (and 23 received post-HDCT/aSCT RT) with a 5-year PFS of 53.3% (95% CI, 41.8%-67.9%) and OS of 66.5% (95% CI, 54.9%-80.5%).</p><p><strong>Conclusion and relevance: </strong>In this nonrandomized clinical trial, FDG-PET response-guided salvage in relapsed cHL may identify patients in whom transplant-free salvage achieves excellent outcomes. HDCT/aSCT may be reserved for primary progression and relapsed cHL with inadequate response.</p><p><strong>Trial regi","PeriodicalId":48661,"journal":{"name":"Jama Oncology","volume":" ","pages":"258-267"},"PeriodicalIF":28.4,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11926631/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142916044","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Patient-Reported Outcomes for Low-Risk Ductal Carcinoma In Situ: A Secondary Analysis of the COMET Randomized Clinical Trial.","authors":"Ann H Partridge, Terry Hyslop, Shoshana M Rosenberg, Antonia V Bennett, Sarah Drier, Mattias Jonsson, Ayako Shimada, Yutong Li, Yan Li, Thomas Lynch, Elizabeth Frank, Deborah Collyar, Desiree Basila, Donna Pinto, Anna Weiss, Anna Wolf, Kelsey Norris, Meredith Witten, Marc Boisvert, Armando Giuliano, Kelsey E Larson, Kathleen Yost, Priscilla F McAuliffe, Amy Krie, Nina Tamirisa, Sonja Darai, Lisa Carey, Alastair Thompson, E Shelley Hwang","doi":"10.1001/jamaoncol.2024.6556","DOIUrl":"10.1001/jamaoncol.2024.6556","url":null,"abstract":"<p><strong>Importance: </strong>Active monitoring (AM) for low-risk ductal carcinoma in situ (DCIS) has been considered as a potential alternative to guideline-concordant care (GCC; inclusive of surgery with or without radiation). Reported data comparing patient-reported outcomes (PROs) between GCC and AM for DCIS are lacking.</p><p><strong>Objective: </strong>To compare PROs at baseline and over time in patients with low-risk DCIS randomized to receive either AM or GCC.</p><p><strong>Design, setting, and participants: </strong>This prespecified secondary outcome analysis used prospectively collected validated questionnaires at baseline, 6 months, 1 year, and 2 years from participants enrolled from June 2017 to January 2023 in the Comparing an Operation to Monitoring, With or Without Endocrine Therapy (COMET) study for low-risk DCIS, which randomized participants to receive GCC or AM.</p><p><strong>Intervention: </strong>Randomization to GCC or AM.</p><p><strong>Main outcomes and measures: </strong>Context-relevant PROs, including health-related quality of life, anxiety, depression, and symptoms measured by validated survey instruments. Mixed models, including sensitivity analyses, with group, point, and group-by-point effects were used to compare PROs between groups.</p><p><strong>Results: </strong>Of the 957 participants in COMET, 225 (24%) were younger than 55 years at enrollment, 325 (34%) were aged 55 to 65 years, and 403 (42%) were older than 65 years, and 953 (99.5%) completed questionnaires at some point within the first 2 years, with a completion rate of more than 83% at all points. Quality of life, anxiety, depression, worries about DCIS, and symptom trajectories were comparable between groups, with modest fluctuations over time of limited clinical significance. Physical functioning was the only specific Medical Outcomes Study 36-item short-form health survey (SF-36) domain for which changes in the score trajectory differed by group over time, with mean scores ranging from 50 (baseline) to 48 (6, 12, and 24 months) in the GCC group and 50 (baseline) to 47 (12 months) and 48 (6 and 24 months) in the AM group (pooled SD, 9.9; P = .01), although these were also of limited clinical significance.</p><p><strong>Conclusions and relevance: </strong>In this prespecified secondary analysis of the COMET prospective randomized trial, the overall lived experience of women randomized to undergo AM for low-risk DCIS was similar to that of women randomized to GCC during the 2 years following diagnosis.</p><p><strong>Trial registration: </strong>ClinicalTrials.gov Identifier: NCT02926911.</p>","PeriodicalId":48661,"journal":{"name":"Jama Oncology","volume":" ","pages":"300-309"},"PeriodicalIF":28.4,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11908405/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142814754","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}